Protalix Biotherapeutics

Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa, PRX-115 and PRX-11. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Hackensack, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Protalix BioTherapeutics excels in Q2 with milestone achievements and revenue growth

Protalix BioTherapeutics delivered strong financial performance in Q2 2023, driven by milestone achievements and revenue growth.
The company's robust balance sheet, successful product launches, and focus on innovation position it well for future success.
While facing challenges in a competitive market, Protalix has opportunities to expand market presence, drive innovation, and enhance shareholder value.
Strategic execution and continued focus on profitability will be key for Protalix to capitalize on opportunities and navigate industry challenges.

Protalix BioTherapeutics navigates mixed Q3 results, eyes pipeline advancements

Protalix BioTherapeutics reported a mixed financial performance in Q3 2023, with revenue fluctuations and cost management efforts impacting the bottom line. The company remains focused on advancing its pipeline candidates and commercial launches to drive future growth and market success.
Despite challenges in revenue streams and cost structures, Protalix demonstrated operational stability and strategic decision-making in navigating market dynamics. The company's strong leadership team, diverse product portfolio, and ongoing clinical programs position it well for future opportunities and growth.
Overall, Protalix BioTherapeutics showcased resilience amidst external events, with a strategic focus on product approvals, cost optimization, and clinical advancements. The company's financial stability, strong cash reserves, and commitment to innovation underscore its competitive position in the biopharmaceutical industry.

Protalix BioTherapeutics reports stellar Q4 performance and growth opportunities

Protalix BioTherapeutics delivered strong financial results in Q4 2023, driven by the successful launch of Elfabrio and cost-saving measures.
Strategic leadership additions and a robust cash position position the company well for future growth and innovation.
While challenges persist in sustaining growth and managing costs, opportunities in new drug development and market expansion offer promising avenues for Protalix.

Protalix BioTherapeutics reports Q1 progress with promising pipeline advancements

Protalix BioTherapeutics navigated revenue challenges with cost management and maintained financial stability through a strong cash position.
Progress in the pipeline with PRX-115's positive Phase I results and upcoming Phase II trial signals potential growth opportunities.
Analyst inquiries underscore the importance of addressing safety concerns, conducting robust trials, and effectively positioning products in a competitive market.

Protalix BioTherapeutics advances PRX-115 for uncontrolled gout treatment

Protalix BioTherapeutics showcased promising results for PRX-115 in uncontrolled gout, with plans for Phase II trial and a focus on renal rare diseases.
Despite a net loss in Q2 2024, the company's strong cash position supports operations and strategic R&D efforts for future growth.
Challenges in financial performance call for cost management strategies, while opportunities lie in clinical advancements and innovative product development.

Protalix BioTherapeutics reports robust Q3 earnings and advances innovative therapies

Protalix BioTherapeutics delivered strong financial performance in Q3 2024, marked by revenue growth, net income, and debt-free status, showcasing operational efficiency.
PRX-115's positive Phase I trial results and upcoming Phase II trial highlight Protalix's commitment to innovation and advancing novel therapies for unmet medical needs.
While facing challenges in regulatory dynamics and competitive landscape, Protalix has opportunities to leverage its strengths in product development and market expansion for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Protalix Undervalued Due To Ghost Of Shire, Upside On Fabry Approval Significant

Protalix Should Go Higher If FDA Approves Fabry Disease Therapy

Protalix Bio Therapeutics (PLX) CEO, Dror Bashan on Q1 2020 Results - Earnings Call Transcript

Protalix (PLX) announces submission of regulatory application seeking approval for its lead pipeline candidate, pegunigalsidase alfa, for Fabry disease.

Protalix Submits BLA for Fabry Disease Candidate PRX-102

Protalix BioTherapeutics' (PLX) CEO Dror Bashan on Q4 2019 Results - Earnings Call Transcript

Protalix (PLX) successfully completes the pre-BLA meeting and gets FDA acceptance for using accelerated approval pathway for the BLA submission of Fabry disease candidate, pegunigalsidase alfa.

Protalix Finalizes Accelerated Approval Pathway for PRX-102

Protalix BioTherapeutics, Inc. (PLX) CEO Dror Bashan on Q3 2019 Results - Earnings Call Transcript

Protalix (PLX) delivered earnings and revenue surprises of 50.00% and 22.83%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Protalix (PLX) Reports Q3 Loss, Tops Revenue Estimates

Protalix (PLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Protalix (PLX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Protalix (PLX) completes enrollment in another phase III study of pegunigalsidase alfa (PRX 102) to treat Fabry disease.

Protalix Completes Enrollment in Third Fabry Disease Study

CARMIEL, Israel, Aug.  30, 2019  (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins including a late-stage clinical product expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that it received a deficiency letter from NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the continued listing standards as set forth in Section 1003(a)(i) – (iii) of the NYSE American Company Guide (the “Company Guide”) as it has reported a stockholders’ equity deficiency as of June 30, 2019 and net losses in its five most recent fiscal years ended December 31, 2018.

Protalix BioTherapeutics Receives Listing Deficiency Letter from NYSE American

CARMIEL, Israel, Aug.  22, 2019  (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced that it has engaged a first-tier financial advisory firm to assist the Company in evaluating and pursuing strategic alternatives to maximize stakeholder value.

Protalix BioTherapeutics Focuses on Evaluating and Pursuing Alternatives to Maximize Shareholder Value through Refinancing & Strategic Partnerships

Protalix Biotherapeutics, Inc. (PLX) CEO Dror Bashan on Q2 2019 Results - Earnings Call Transcript

Protalix (PLX) delivered earnings and revenue surprises of -66.67% and 4.23%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Protalix (PLX) Reports Q2 Loss, Tops Revenue Estimates

Protalix (PLX) closes enrollment in the late-stage study on PRX-102, currently being developed for the treatment of patients with Fabry disease.

Protalix (PLX) Completes Enrollment in Fabry Disease Study

Protalix Biotherapeutics, Inc. (PLX) CEO Moshe Manor on Q1 2019 Results - Earnings Call Transcript

Protalix (PLX) delivered earnings and revenue surprises of -66.67% and 2.85%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Protalix (PLX) Reports Q1 Loss, Tops Revenue Estimates

Protalix (PLX) is scheduled to release its first quarter 2019 results on May 6 and we expect the company to provide updates on the pipeline.

Protalix (PLX) to Report Q1 Earnings: What's in the Cards?

Investors need to pay close attention to Protalix stock based on the movements in the options market lately.

Do Options Traders Know Something About Protalix Stock We Don't?

Protalix BioTherapeutics, Inc. (PLX) CEO Moshe Manor on Q4 2018 Results - Earnings Call Transcript

News for Protalix Biotherapeutics Stock (PLX)